You have no items in your shopping cart.
GLP-1R, GIPR & GCGR Research Reagents
Validated antibodies, ELISA kits, and custom peptide synthesis for mapping multi-agonist incretin therapies and metabolic disease pathways.
1. Target Overview: Class B GPCRs
The pharmacological foundation of modern incretin-based therapies relies on the coordinated activation of specific class B G protein-coupled receptors (GPCRs). The primary clinical and preclinical targets in metabolic disease research are the Glucagon-like peptide 1 receptor (GLP-1R), Glucose-dependent insulinotropic polypeptide receptor (GIPR), and the Glucagon receptor (GCGR).
These receptors regulate critical physiological processes including glucose homeostasis and systemic energy expenditure. Because GPCRs are notoriously difficult to target, researchers require anti-GLP-1R antibodies, anti-GCGR antibodies, and functionally active active recombinant proteins for receptor mapping in FFPE tissues and functional target engagement in in vitro binding assays.
💡
Clinical Focus: Next-generation therapies target multiple GPCRs simultaneously. This synergistic approach maximizes metabolic benefits while mitigating dose-limiting adverse events, such as lean muscle mass decline.
2. The Shift to Dual and Triple Agonism
The research frontier has moved beyond mono-agonists toward unimolecular multi-agonists. Natural double agonists, such as Oxyntomodulin (OXM), activate both GLP-1 and glucagon receptors, leading to appetite suppression and increased lipolysis.
Triple agonists, like the Phase 2 candidate Retatrutide, target GLP-1, GIP, and GCGR. Published data indicate Retatrutide achieves up to 24.2% mean weight loss at 48 weeks in individuals with obesity and substantial improvements in HbA1c (2.2% reduction) for patients with Type 2 Diabetes.
- Hepatic steatosis reduction: Trials recorded up to an 82% reduction in liver fat, emphasizing the necessity of robust lipid metabolism assays.
- Energy expenditure: GCGR activation directly promotes fatty acid oxidation and ketone body formation, establishing a negative energy balance.
3. Intracellular Signaling Pathways (Gs-cAMP/Akt)
Validating the efficacy of these novel multi-agonists requires tracking complex intracellular kinase cascades. When activated, GLP-1R couples to Gs proteins, raising intracellular cyclic AMP (cAMP). This initiates downstream signaling critical for pancreatic beta-cell survivaland insulin exocytosis.
Key downstream targets utilized for functional validation include:
- cAMP secondary messenger cascade: functional confirmation of functional Gs-coupled receptor activation.
- PI3K/Akt pathway & ERK1/2 pathway: Essential signaling routes for beta-cell survival. Phospho-specific Akt antibodies are routinely used in Western blots to quantify this activation.
- AMPK signaling: Monitored in metabolic studies to assess cellular energy states, mitochondrial function, and lipid oxidation.
4. Validated Antibodies & Recombinant Proteins
To accurately track receptor expression in immunohistochemistry (IHC) and measure intracellular signaling, Biorbyt provides high-sensitivity reagents designed for denaturing (WB) and native (binding) biochemical workflows.
Target Focus | Relevant Bioreagents | Validated Applications | Action Guide |
|---|---|---|---|
Receptor Expression Mapping | WB, IHC-P (FFPE), IF | ||
Active Agonists & Controls | Binding Assays, Cell Culture | ||
Signaling Validation | WB (Denaturing), Flow Cytometry |
5. Custom Services: Overcoming GPCR & Ligand Bottlenecks
Developing next-generation incretin therapies requires overcoming two major biochemical hurdles: synthesizing complex multi-target ligands and stabilizing notoriously difficult multi-pass membrane receptors (GPCRs) for binding and structural assays. Biorbyt offers specialized custom expert services to bridge this gap.
🧬
Ligand Engineering
Custom Peptide Synthesis
Synthesize difficult sequences and natural analogs. We support unnatural amino acid substitutions and complex fatty acid conjugations (e.g., di-acid moieties) required to extend half-life.
⚡
Receptor Stabilization
Full Membrane Protein Expression
Utilizing advanced synthetic nanodiscs and Virus-Like Particles (VLPs), we deliver functionally active Class GPCRs for your native conformation assays.
🛡
Advanced Targeting
Custom Nanobody Development
Generate single-domain VHH antibodies to access hidden GPCR extracellular loops and stabilize active receptor conformations during structural studies.
🔬
Need standard downstream targets?
If your assay requires standard kinases or downstream signaling targets, utilize our standard Recombinant Protein Expression services across mammalian and E. coli systems.
6. ELISA Kits & Metabolic Assays
Tracking the systemic outcomes of novel therapies requires sensitive quantification of secondary messengers(cAMP), metabolic markers, and adipokines in biological fluids or cell lysates.
secondary messenger Assay
cAMP ELISA Kits
functional quantification of functional intracellular cAMP accumulation to functionally confirm functional Gs-protein coupled GPCR activation.
Hormone Quantification
Insulin & GLP-1 ELISA
Quantify active incretin levels and track downstream insulin secretion in clinical serum samples or animal models.
Liver Health Models
Triglyceride & Lipid Assays
Essential tools for evaluating functional reduction of hepatic steatosis in preclinical NASH/MASLD models.
7. Essential Workflow Reagents
Ensure reliable, reproducible results when tracking Akt/ERK pathways or mapping difficult GPCR targets by utilizing Biorbyt’s optimized workflow support reagents.
- 🧬 Protease & Phosphatase Inhibitor Cocktails: Crucial for preserving phosphorylation states in lysates for Phospho-Akt/ERK Western blots.
- 🔭 Loading Control Antibodies: Heavily validated GAPDH, Beta-Actin, and Tubulin antibodies for accurate Western blot protein quantification.
- ➤ Secondary Antibodies: High-affinity HRP and fluorescent-conjugated secondary antibodies optimized for low background in IHC and WB.
📚 8. Scientific Citations & Bibliography
The technical data, therapeutic targets, and multi-agonist signaling mechanisms outlined in this page are sourced from the following recent literature.
- 🔖 Filippatos, T. D., et al. (2025). Triple Agonism Based Therapies for Obesity. European Journal of Clinical Investigation, 55(2), e14321.
https://onlinelibrary.wiley.com/doi/10.1111/eci.14321 - 🔖 Goldney, J., et al. (2025). Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports, 19(1), 18.
https://pubmed.ncbi.nlm.nih.gov/40741227/ - 🔖 Frias, C. E., et al. (2025). Incretin-Based Multi-Agonist Therapies for Type 2 Diabetes Mellitus and Obesity: Mechanisms, Clinical Efficacy, and Future Directions. Endocrines, 7(3), 46.
https://www.mdpi.com/2673-4540/7/3/46 - 🔖 Zhang, J., et al. (2025). Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity. International Journal of Molecular Sciences, 26(4), 1651.
https://www.mdpi.com/1422-0067/26/4/1651 - 🔖 Nauck, M. A. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism, 18(3), 203-216.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4785614/ - 🔖 von Haehling, S., et al. (2025). Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. Journal of Cachexia, Sarcopenia and Muscle, 16(6), e70147.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12686571/ - 🔖 Literature on GLP-1 and Incretin Mechanisms (2025). Pharmacology & Therapeutics.
https://www.sciencedirect.com/science/article/pii/S0163725825000361